ADC CDMO Market (2026-2036)

The growth of this market is mainly driven by the rapid growth of the global ADC pipeline and the number of approved ADCs, the high share of ADC development and manufacturing that is outsourced because of the need for highly potent compound handling and specialized bioconjugation capabilities, the large volume of ADC licensing deals between Chinese biotechs and global pharmaceutical companies, and the shift of many ADC programs from clinical to commercial manufacturing. However, factors such as the high capital cost and long lead time of building containment facilities for highly potent payloads and the complexity of technology transfer and supply chain coordination across antibody, payload-linker, conjugation, and fill-finish steps are expected to restrain the growth of this market to some extent.

Antibody-drug conjugates combine a monoclonal antibody that targets cancer cells or other diseased cells with a highly potent drug, called the payload, joined by a chemical linker. The antibody carries the payload directly to the target cells, which allows much more potent drugs to be used than in conventional chemotherapy while limiting damage to healthy tissue. ADCs have become one of the fastest-growing classes of cancer drugs, led by products such as Enhertu, Padcev, and Trodelvy, and as of mid-2026, 23 ADCs had been approved worldwide, with many more in late-stage development. China approved the world's first bispecific ADC in June 2026, and ADCs are increasingly being tested in earlier lines of treatment, where patient numbers and treatment durations are larger.

Manufacturing ADCs is complex and requires several distinct capabilities, because the antibody must be produced in mammalian cell culture, the payload and linker must be synthesized as highly potent active pharmaceutical ingredients (HPAPIs) in facilities with strict containment, the antibody and payload-linker must be joined in a bioconjugation step under highly potent containment, and the final drug product must be filled and finished, often as a lyophilized powder, in sterile facilities that can handle cytotoxic products. Few drug developers have all of these capabilities in-house, which is why a large share of ADC development and manufacturing is outsourced to CDMOs. Each step also has its own regulatory requirements, and sponsors must show regulators that the whole chain is controlled, which favors experienced partners.

The ADC CDMO market includes several types of providers, with large integrated CDMOs, such as Lonza, WuXi XDC, Samsung Biologics, and Catalent, offer antibody production, payload-linker synthesis, conjugation, and fill-finish at commercial scale. Specialist bioconjugation CDMOs, such as Piramal Pharma Solutions, Abzena, Sterling Pharma Solutions, and Ajinomoto Bio-Pharma Services, focus on conjugation and related services, while HPAPI specialists, such as Axplora, Veranova, and CordenPharma, supply payloads and linkers. Fill-finish specialists, such as BSP Pharmaceuticals, provide sterile drug product capacity for cytotoxic ADCs. Merck KGaA's MilliporeSigma operates a dedicated bioconjugation center of excellence in St. Louis, and new entrants such as Lotte Biologics have built ADC facilities in the U.S.

Demand for ADC CDMO services is growing quickly because of the size and maturity of the ADC pipeline. Hundreds of ADCs are in clinical development, and many are moving from early trials to late-stage studies and commercial launch, which requires larger-scale and more complex manufacturing. WuXi XDC alone reported 226 integrated ADC projects at the end of 2025, and Lonza states that it manufactures the majority of commercially available ADCs. The number of new ADC approvals is expected to increase over the forecast period as late-stage programs from global pharmaceutical companies and Chinese biotechs reach the market.

China has become a major source of ADC innovation, as Chinese biotechs have developed a large number of ADCs and licensed many of them to global pharmaceutical companies, and Chinese drugmakers signed a record USD 135.7 billion in cross-border out-licensing deals in 2025, with ADCs among the most active categories. Many of these programs were developed with Chinese CDMOs such as WuXi XDC, and as they move into global trials and commercial supply, they create demand for capacity in China, Singapore, Europe, and the U.S. At the same time, concerns about supply chain security and possible U.S. restrictions on Chinese biotechnology suppliers are encouraging some sponsors to dual-source or move manufacturing to Western and other Asian CDMOs.

CDMOs are responding with a wave of capacity investments, as Lonza is expanding bioconjugation capacity in Visp and development capacity in Oss, WuXi XDC is adding capacity in Wuxi and Singapore, Merck KGaA is tripling capacity in St. Louis, Sterling Pharma Solutions has more than doubled capacity in Deeside, and Samsung Biologics and Lotte Biologics have launched ADC services. Many of these investments focus on larger-scale commercial suites and integrated services that combine antibody, payload-linker, conjugation, and fill-finish steps, which reduce technology transfer risk and shorten timelines for customers. Despite this investment, many sponsors report that commercial-scale conjugation and cytotoxic fill-finish slots remain hard to secure, especially for launches planned in the next few years.

We licensed two ADCs from China, and we now need commercial supply in Europe and the U.S. as well as in Asia. Securing conjugation and cytotoxic fill-finish capacity years ahead has become one of our top priorities.

The licensing of ADC assets by large pharma and their need for diversified commercial capacity are driving the fast growth of the large pharmaceutical companies segment and the commercial and fill-finish segments.

Our partners want global-standard manufacturing and a second source outside China. We are working with CDMOs that have sites in Singapore and Europe so that our programs can move smoothly into global trials.

Global licensing and supply chain diversification are supporting rapid growth in Asia-Pacific, the fastest-growing region at a CAGR of 18.1%, along with new capacity in Singapore and South Korea. Chinese developers increasingly see dual-source manufacturing as a condition for successful global licensing.